Blood-Based Biomarkers and Risk of Onset of Mild Cognitive Impairment Over the Short and Long Term
Results indicate that during preclinical AD, more abnormal blood biomarker levels of amyloid (Aβ<sub>42</sub>/Aβ<sub>40</sub>), p-tau<sub>181</sub>, neurodegeneration (NfL), and neuroinflammation (GFAP) individually are associated with progression from normal cognition to MCI, but the AD-nonspecific neurodegeneration and inflammation markers were not associated with symptom onset after accounting for amyloid and p-tau levels.
Authors
- Anja Soldan (ORCID: https://orcid.org/0000-0002-6193-0418)
- Jiangxia Wang (ORCID: https://orcid.org/0000-0002-1715-3981)
- Marilyn Albert (ORCID: https://orcid.org/0000-0002-8167-8985)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Corinne Pettigrew
- Abhay Moghekar (ORCID: https://orcid.org/0000-0001-9464-1551)
- Tobias Bittner (ORCID: https://orcid.org/0000-0001-9256-0360)
Institutions
- Roche (Switzerland) (CH)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sahlgrenska University Hospital (SE)
- Sorbonne Université (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut du Cerveau (FR)
- University of Gothenburg (SE)
Publication Details
- Journal
- Neurology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1212/wnl.0000000000210225
- Citations
- 10
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 3.86
Funders
- National Institutes of Health
- National Institute of Mental Health